<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628325</url>
  </required_header>
  <id_info>
    <org_study_id>UPalermo</org_study_id>
    <nct_id>NCT04628325</nct_id>
  </id_info>
  <brief_title>Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)</brief_title>
  <official_title>Effects of Treatment With Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS) on Atrial Stretching, Fibrosis and Inflammatory Markers in Subjects With Heart Failure With Reduced Ejection Fraction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Palermo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Palermo</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators sought to evaluate the effectiveness of treatment with furosemide + HSS in&#xD;
      terms of reduction of serum levels of some chosen markers of heart failure and the response&#xD;
      in terms of these markers at a compensated state after an acute saline load.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All consecutive patients aged &gt;18 years with a diagnosis of acute heart failure or&#xD;
      exacerbation in chronic heart failure due to heart failure with reduced ejection fraction (&#xD;
      HFrEF) admitted to the ward of Internal Medicine were enrolled from March 2017 to June 2019.&#xD;
      Enrolled subjects were treated with treatment with hypertonic saline solutions + furosemide&#xD;
      e.v and control subjects with congestive heart failure randomized to treatment with&#xD;
      intravenous furosemide only. Chronic kidney disease patients undergoing dialysis replacement,&#xD;
      acute coronary syndrome, myocarditis, pneumonia, myopathies, neoplasms have been excluded.&#xD;
&#xD;
      Patients underwent at T0 (at 24 hours from admission), T1 (after 6-8 days after treatment&#xD;
      with high dose furosemide+ HSS ), T2 (after a saline load) venepuncture to obtain venous&#xD;
      blood samples for the determination of serum concentrations of N terminal pro B-type&#xD;
      natriuretic peptide, High-sensitive cardiac troponin T, Galectin 3, IL-6.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of Treatment With Moderate/High Doses of Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS) on Atrial Stretching</measure>
    <time_frame>6 days</time_frame>
    <description>Assessment of differences between participants on atrial diameters evaluated with echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of Treatment With Moderate/High Doses of Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS) on Atrial Fibrosis</measure>
    <time_frame>6 days</time_frame>
    <description>Assessment of differences between participants on atrial fibrosis evaluated with echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of Treatment With Moderate/High Doses of Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS) on Inflammatory Markers</measure>
    <time_frame>6 days</time_frame>
    <description>Evaluation of serum level of cytokines linked to inflammation and cardiac damage (IL-6, High-sensitive cardiac troponin T, Soluble interleukin 1 receptor-like 1, Galectin-3, N Terminal proB-type natriuretic peptide, C Reactive Protein)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Heart Failureï¼ŒCongestive</condition>
  <arm_group>
    <arm_group_label>high dose furosemide plus HSS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated high dose furosemide plus HSS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose furosemide alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated high dose furosemide alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)</description>
    <arm_group_label>high dose furosemide alone</arm_group_label>
    <arm_group_label>high dose furosemide plus HSS</arm_group_label>
    <other_name>Furosemide plus HSS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Congestive Heart Failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute myocarditis&#xD;
&#xD;
          -  active pulmonary or liver diseases&#xD;
&#xD;
          -  autoimmune disorders&#xD;
&#xD;
          -  infections&#xD;
&#xD;
          -  malignant diseases&#xD;
&#xD;
          -  muscle disorders&#xD;
&#xD;
          -  renal insufficiency&#xD;
&#xD;
          -  chronic inflammatory diseases&#xD;
&#xD;
          -  rheumatological diseases&#xD;
&#xD;
          -  haematological diseases&#xD;
&#xD;
          -  chronic treatment with anti-inflammatory drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonino Tuttolomondo, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Internal Medicine and Stroke Care Ward, University of Palermo, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AOUP Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Ward of Palermo University Hospital</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Palermo</investigator_affiliation>
    <investigator_full_name>Antonino Tuttolomondo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>HFrEF</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Atrial Stretching</keyword>
  <keyword>Furosemide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

